Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Yuzaiful Md Yusof"'
Autor:
Laurent Arnaud, Savino Sciascia, Karen Hambly, Ioannis Parodis, Md Yuzaiful Md Yusof, Ivan Padjen, Anselm Mak, Manuel F Ugarte-Gil, Saira Z Sheikh, Linda Li, Alexandra Legge, Alberto Soriano-Maldonado, Dominique Kinnett-Hopkins, Thomas Davergne, Sophie Geneton, Julien Blaess, Thibaut Goepfert, Gabriel Bordier, Yurilis Fuentes, Håvard Haglo, Kuei-Ying Su
Publikováno v:
RMD Open, Vol 10, Iss 2 (2024)
Objective This international task force aimed to provide healthcare professionals and persons living with systemic lupus erythematosus (SLE) with consensus-based recommendations for physical activity and exercise in SLE.Methods Based on evidence from
Externí odkaz:
https://doaj.org/article/bf9d32032f944c499decfbe382cf84d5
Autor:
Khaled Mahmoud, Edward M Vital, Md Yuzaiful Md Yusof, Porntip Intapiboon, Sabih Ul Hassan, Jack Arnold
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/fcbc7ec8d6414ebab55270712f34c4d1
Autor:
Edward M Vital, Darren Plant, Md Yuzaiful Md Yusof, Zoe Wigston, Antonios Psarras, Adewonuola Alase, Lucy Marie Carter, Julien Bauer, Stephanie Wenlock
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/279d1ef1cc534650b8bc1950a30850ba
Autor:
Sophanit Pepple, Jack Arnold, Edward M. Vital, Andrew C. Rawstron, Colin T. Pease, Shouvik Dass, Paul Emery, Md Yuzaiful Md Yusof
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 8, Pp 689-699 (2022)
Objective To assess outcomes of repeat rituximab cycles and identify predictors of sustained clinical response in systemic manifestations of primary Sjögren syndrome (pSS). Methods An observational study was conducted in 40 rituximab‐treated patie
Externí odkaz:
https://doaj.org/article/7ae5ada849e9491e9254c581086d8410
Autor:
James I. Robinson, Md Yuzaiful Md Yusof, Vinny Davies, Dawn Wild, Michael Morgan, John C. Taylor, Yasser El-Sherbiny, David L. Morris, Lu Liu, Andy C. Rawstron, Maya H. Buch, Darren Plant, Heather J. Cordell, John D. Isaacs, Ian N. Bruce, Paul Emery, Anne Barton, Timothy J. Vyse, Jennifer H. Barrett, Edward M. Vital, Ann W. Morgan
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104343- (2022)
Summary: Background: Rituximab is widely used to treat autoimmunity but clinical response varies. Efficacy is determined by the efficiency of B-cell depletion, which may depend on various Fc gamma receptor (FcγR)-dependent mechanisms. Study of FcγR
Externí odkaz:
https://doaj.org/article/737647859b7c4fa4b27b129f6871d9c8
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Externí odkaz:
https://doaj.org/article/e0cc490bb0eb4907b371d95cf1a49b71
Autor:
Antonios Psarras, Adewonuola Alase, Agne Antanaviciute, Ian M. Carr, Md Yuzaiful Md Yusof, Miriam Wittmann, Paul Emery, George C. Tsokos, Edward M. Vital
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Type I interferon drives autoimmune pathology in SLE and has been assumed to come predominantly from plasmacytoid dendritic cells (pDCs). Here, the authors show that prior to the onset of SLE, pDCs lose multiple immunogenic functions and, instead, no
Externí odkaz:
https://doaj.org/article/bbb2318833484129bd8e0fdec78640c3
Autor:
Jack Arnold, Edward M. Vital, Shouvik Dass, Aamir Aslam, Andy C. Rawstron, Sinisa Savic, Paul Emery, Md Yuzaiful Md Yusof
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
BackgroundTime to relapse after rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is variable, and optimal retreatment strategy has remained unclear. In AAV following rituximab induction, the study
Externí odkaz:
https://doaj.org/article/a4e04aba48d646c89c46ddaebab40462
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
Background: Rituximab is commonly used for systemic lupus erythematosus (SLE) but secondary non-depletion and non-response (2NDNR) associated with anti-drug antibodies is a notable problem with repeat rituximab cycles. Other B cell-targeted therapies
Externí odkaz:
https://doaj.org/article/bfebe863271f411eaa4382598f1f9660
Autor:
Jack Arnold, Shouvik Dass, Sarah Twigg, Colin H Jones, Ben Rhodes, Peter Hewins, Mithun Chakravorty, Phil Courtney, Michael Ehrenstein, Md Yuzaiful Md Yusof, Edward M Vital
Publikováno v:
Rheumatology. 61:4905-4909
Objectives Secondary inefficacy with infusion reactions and anti-drug antibodies (secondary non-depletion nonresponse, 2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8e0a2cfb7c5bd285c34dd6ad14dbcd1
https://doi.org/10.1093/rheumatology/keac150
https://doi.org/10.1093/rheumatology/keac150